ISCO International Stem Cell Corp. to Host Third Q
Post# of 94146
Posted On: 11/06/2013 8:40:30 AM
ISCO International Stem Cell Corp. to Host Third Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Wednesday, Nov...
International Stem Cell Corporation to Host Third Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Wednesday, November 13, 2013
CARLSBAD, CA--(Marketwired - Nov 6, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Wednesday, November 13, 2013 to discuss its financial results for the three and nine months ended September 30, 2013.
Dr. Simon Craw, Executive Vice President and Mr. Jay Novak, Chief Financial Officer of International Stem Cell will host the conference call. To attend the call, please use the dial in information below:
Date: Wednesday, November 13, 2013
Time: 11:00 a.m. Eastern Time
Conference Line (U.S.): 1-877-941-1428
International Dial-In: 1-480-629-9665
Conference ID: 4648561
Webcast: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1293
Please dial in at least 10-minutes before the call to ensure timely participation.
A playback of the call will be available until 11:59 pm ET on November 27, 2013. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin 4648561.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Follow us for industry related news on Facebook at www.facebook.com/InternationalStemCellCorporation and Twitter at www.twitter.com/intlstemcell
Forward-looking Statements
Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383
Email: ir@intlstemcell.com
International Stem Cell Corporation to Host Third Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Wednesday, November 13, 2013
CARLSBAD, CA--(Marketwired - Nov 6, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Wednesday, November 13, 2013 to discuss its financial results for the three and nine months ended September 30, 2013.
Dr. Simon Craw, Executive Vice President and Mr. Jay Novak, Chief Financial Officer of International Stem Cell will host the conference call. To attend the call, please use the dial in information below:
Date: Wednesday, November 13, 2013
Time: 11:00 a.m. Eastern Time
Conference Line (U.S.): 1-877-941-1428
International Dial-In: 1-480-629-9665
Conference ID: 4648561
Webcast: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1293
Please dial in at least 10-minutes before the call to ensure timely participation.
A playback of the call will be available until 11:59 pm ET on November 27, 2013. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin 4648561.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Follow us for industry related news on Facebook at www.facebook.com/InternationalStemCellCorporation and Twitter at www.twitter.com/intlstemcell
Forward-looking Statements
Statements pertaining to anticipated developments, the potential benefits of research programs and products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Phone: 760-940-6383
Email: ir@intlstemcell.com
(0)
(0)Scroll down for more posts ▼